anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Hemoglobin cross-linked with disulfide linkages at sites external to the native globin chains is prepared by reacting hemoglobin with site-directed reagents exemplified by N,N&#39;-bis Cbz-cysteinyl bis (methyl phosphate).  Reaction with deoxy hemoglobin produces two main products: cross-linked hemoglobin as the bis cysteinyl amide of the .epsilon.-amino group of the side chain of Lys-82 of the two .beta. subunits, and modified but non-cross-linked hemoglobin that has each of the same amino groups modified as the cysteinyl amide. Disulfide cross-linked hemoglobin has a variety of uses. The disulfide bonds can be cleaved with reducing agents to give terminal sulfhydryl groups, useful in chemical bonding to sulfhydryl group-containing biochemically active compounds to form conjugates thereof for drug delivery. Hemoglobin cross-linked through disulfide bonds can be formed from the sulfhydryl group terminated reduction products, for use as a hemoglobin-based oxygen carrier.
PURPOSE:To prevent the infection of cattle with Salmonella dublin, by administering the cattle with a specific strain derived from Salmonella dublin. CONSTITUTION:A Salmonella dublin-derived strain (P&lt;-&gt;) devoid of the plasmid having a molecular weight of 50 mega-dalton is administered to cattle to prevent the infection of the cattle with Salmonella dublin. P&lt;-&gt; can be prepared by culturing Salmonella dublin in a medium containing ethidium bromide at the maximum concentration to enable the growth of the strongly toxic wild strain of Salmonella dublin. There is no particular restriction in the method of administration, and the agent can be administered by intramuscular injection, etc. as well as subcutaneous injection and intravenous injection. The dose can be determined properly. It can be administered at a high dose because of its high safety. P&lt;-&gt; is useful as a live vaccine for the prevention of Salmonella dublin infection.
A method for inactivating target cells in the presence of T cells by bringing the two types of cells in contact with a superantigen (SAG) in the presence of an immune modulator, characterized in that at least one of the superantigen and the immune modulator is in the form of a conjugate between a &#34;free&#34;  superantigen (Sag) and a moiety targeting the conjugate to the target cells. A  superantigen conjugate complying with the formula (I): (T)x(Sag)y(IM)z; a) T  is a targeting moiety, Sag corresponds to a free superantigen, IM is an immune modulator that is not a superantigen and T, Sag and IM are linked together via organic linkers B; b) x, y and z are integers that typically are selected among 0-10 and represent the number of moieties T, Sag and IM, respetively, in a given conjugate molecule, with the provision that y &gt; 0 and also one or both of x and z &gt; 0. The superantigen conjugate is preferably a triple fusion protein. A targeted immune modulator, characterized in that it is a conjugate between a targeting moiety (T&#39;&#39;&#39;) and a modified immune modulator (IM&#39;&#39;&#39;). The conjugate complies with a formula analogous to formula (I) except for the imperative presence of the modified immune modulator. A superantigen moiety may be present. A DNA molecule encoding a superantigen and an immune modulator.
In a new procedure for the conversion of an antiinflammatory steroid which undergoes crystal growth in chlorofluorinated aerosol propellants into a crystalline form which is not susceptible to this crystal growth, the steroid is crystallised from ethyl acetate and the prod. obtd. is micronised. New antiinflammatory steroid aerosol preparations contain a steroid which has been subjected to the above procedure. The new procedure prevents steroid crystal growth to a size (&gt;20 mu) unsuitable for administration by inhalation. The procedure is simple, proceeds in almost 100% yield, and avoids the use of toxic materials (ethyl acetate has a rat LD50 of 11.3 g/kg. p.o., and gives no toxic effects when administered to rats and mice in a dosage of 1 g/kg. for 30 days.
1,143,589. 2 - Amino - 4 - hydroxytoluene. L&#39;OREAL. 7 April, 1966 [6 May, 1965], No. 3274/68. Divided out of 1,143,588. Heading C2C. 2 - Amino - 4 - hydroxytoluene is prepared by reacting p-cresol with a compound capable of protecting the phenol function, nitrating the benzene ring of the reaction product in mposition with respect to the protected phenol function, reducing the nitro group to an amino group and then liberating the phenol function. In the example 4-hydroxytoluene is reacted with methane sulphochloride, the mesylated product is dissolved in sulphuric acid and nitrated with a mixture of nitric and sulphuric acids, the nitrated product is reduced with tin and hydrochloric acid and the amino compound produced is hydrolysed with sodium hydroxide to obtain 2-amino-4-hydroxy-toluene.
A composition for tissue degradation and removal and disinfection is provided for dental and medical applications. It can function as a single intra-canal irrigant that eradicates microorganisms as it facilitates the debridement of a root canal system. It contains one or more hydoxides, a thioglycolate compound, sodium hypochlorite, sodium chloride, sodium chlorate, oxygen, and water, such as lime water and purified water, The thioglycolate compound is capable of degrading a cell by disrupting disulfide bonds in its proteins. The sodium hypochlorite enhances its function. The composition may also incorporate mineral oil, urea, cetearyl alcohol, D&amp;C yellow No. 8, chromium hydroxide, theobroma cocoa seed butter, iron oxides, fragrances, lanolin, and/or ceteareth-20. It is effective against Enterococcus faecalis.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in breast cancer cells.  &lt;P&gt;SOLUTION: The polynucleotides are useful in a variety of diagnostic and therapeutic methods. The methods of reducing growth of breast cancer cells are further provided. These methods are useful for treating breast cancer cells. The method and composition, useful for detection of cancerous cells, identification of factors controlling the expression type of cancerous cells, and identification of the therapeutic target of chemotherapy of cancerous cells, are provided.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a gypsum composition for dental models capable of preventing from bacterial infections and excellent in preservation stability by blending a chlorinated isocyanuric acid and a specific compound capable of generating an active halogen. SOLUTION: In this gypsum composition for dental models, 0.02-3wt.% of at least one compound capable of generating an active halogen selected from a group consisting of a chlorinated isocyanuric acid and its salt and a halogenated dimethylhydantoin is blended to gypsum. The composition expresses expected bactericidal and disinfecting effects in its use. As the chlorinated isocyanuric acid and its salt, e.g. trichloroisocyanuric acid, dichloroisocyanuric acid, etc., can be cited. As the halogenated dimethylhydantoin, 1,3-dibromo-5,5- dimethylhydantoin, 1,3-dichloro-5,5-dimethylhydantoin, etc., can be cited. The compound capable of generating an active halogen can be preferably granular and &gt;=95% of the compound comprise particles having 0.15-0.60mm particle size.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a tyrosinase activity inhibitor and/or a lipoxygenase activity inhibitor derived from a natural plant Alpinia speciosa and having high safety and to provide a medicine, a cosmetic or a food preserving agent as uses thereof.  &lt;P&gt;SOLUTION: The tyrosinase or/and lipoxygenase activity inhibitors comprise an extract from the Alpinia speciosa, especially an extract from a rhizome of the Alpinia speciosa as an active ingredient. An external preparation for skin and the cosmetic are obtained by formulating the inhibitors. A therapeutic agent for inflammatory diseases is prepared by formulating the inhibitor having lipoxygenase activity inhibitory actions. The food preserving agent is obtained by formulating the inhibitors having the tyrosinase or/and lipoxygenase activity inhibitory actions.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
Process for the preparation of d,l-5-methyltetrahydrofolic acid and its salts of the formula 1 in which X is hydrogen, an alkali metal or the equivalent of an alkaline earth metal, by reduction of folic acid with NaBH4 and methylation of the tetrahydrofolic acid obtained with aqueous solutions of formaldehyde and sodium borohydride in an inert gas atmosphere. The process is simple and can be carried out without separation of intermediates while carrying out the process steps successively in the same reaction vessel. The final products are obtained in a yield of more than 80%, relative to folic acid employed, in a purity of more than 99%. The compounds of the formula I obtained are non-toxic, stable at physiological pH and suitable for the preparation of liquid or solid pharmaceutical compositions for any type of application in human therapy. Such compositions exhibit haematopoietic action, hepatoprotective and antineoplastic action. &lt;IMAGE&gt;
PURPOSE:To provide a hypocholesteric agent containing tocopherol-enriched poultry egg as an active component and effective to remarkably decrease the total serum cholesterol and HDL-cholesterol, etc., compared with an egg simply added with tocopherol. CONSTITUTION:For example, a commercially available formula feed for laying hen is added with a deodorization distillate of refined soybean (tocopherol- contents, alpha 2.23%, beta 0.16%, gamma 9.96% and delta 3.12%; free fatty acid content, 21%) in an amount of 1.5% to obtain a feed having a VE value of 940. A Highline- breed laying hen is fed continuously with said feed and the laid egg is used as a tocopherol-enriched egg. The total tocopherol content in the yolk of the egg is &gt;=50mg%. The enriched egg exhibits remarkable lipid-metabolizing effect compared with an egg added simply with tocopherol. The egg is compounded to foods, drinks, medicines or formula feed for animal to decrease the cholesterol level of man and domestic animal.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a novel anti-inflammatory agent.  &lt;P&gt;SOLUTION: A composition for treating collagenolytic or inflammatory diseases or disorders comprises a shark cartilage extract as an active ingredient. The shark cartilage extract is a supernatant fraction obtained after centrifugation of an aqueous homogenate of an intact shark cartilage. The fraction is recovered by fractionating the supernatant on a membrane possessing a molecular weight cut-off of 500 kDa. The composition has molecules having molecular weights of &lt;500 kDa and possesses an anti-collagenolytic activity and an anti-inflammatory activity.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
The invention discloses novel fatty carboxylic acid salts of organofunctional silicone amines. The amino pendant functionality is present within the polymer. Compounds of the invention by virtue of their being salts, deposit on the surface of various substrates. Thereby altering the substrate&#39;s surface physical properties. The desirable durable properties which can be given to substrates include; softness, lubrication, soil release, and hydrophobicity. The compounds of the present invention are prepared by the neutralization of a silicone amine with a fatty carboxylic acid.
PURPOSE:To provide a cell strain capable of producing a large amount of an anti-Rh(D) antibody having high specificity. CONSTITUTION:A cell strain producing a monoclonal antibody which does not agglutinate the Rh(D)-minus hemocyte but agglutinates Rh(D) and Rh(D&lt;u&gt;)-plus hemocyte. The cell strain can be obtained by the following process. The human peripheral blood having anti-Rh(D) antibody is collected in the presence of heparin, and the lymphocyte is separated by the Ficol-Conray specific gravity centrifugal separation. Separately, a cell producing and releasing EB virus (e.g. B95-8) is cultured and the supernatant liquid of the culture liquid is separated to obtain a virus source (EB virus liquid). The EB virus liquid is made to contact with the above lymphocyte, and inoculated and cultured on a plate medium at various culture densities. The supernatant liquid of the culture medium is collected when the proliferation of the cell is observed. The liquid is screened by the antibody activity, and the fraction having positive antibody activity is cloned.
694,469. Furniture frames. KNOLL ASSOCIATES, Inc. July 11, 1951, No. 16404/51. Class 52(ii) A chair &amp;c. construction comprises a seat connected with a shell-like . body having an aperture in its centre portion and shaped so as to include a back rest and means or parts adapted to underlie the seat, at least part of the body surface adjacent to the aperture presenting unidimensional curves which are traceable by a straight line generatrix perpendicular t&#39;o the edge of the aperture. Fig. 1 shows a chair with a shell-like body 32 with parts 40, 42 underlying the seat 20 which is mounted on a support 22. The body may be formed from two blanks 32a, 32b, Fig. 3, of bendable material such as metal, plywood or plastic which after being bent to the forms shown in Fig. 1, are connected at 46 and if desired at 48, the curves bordering the central aperture 44 being generated by straight lines G. Arm rests are formed by the parts 36 and the seat 20 projects rearwardly through the central aperture 44. Fig. 5 shows another construction in which the shell-like body 132 is formed from a single blank or may be moulded. Arm rests are omitted in this form. Upholstery in the form of foam rubber pads secured to the surfaces and covered by slip-on material may be provided.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a carbonylation inhibiting agent capable of inhibiting carbonylation of a protein such as keratin, a skin care preparation for external use having enhancing effects on moisture-retaining properties of the skin, and to provide a method for achieving the above effects.  &lt;P&gt;SOLUTION: The carbonylation inhibiting agent for the protein contains at least one effective ingredient selected from among vitamin E and its derivatives, vitamin C and its derivatives and salts thereof, rutin and its derivatives, ginkgo extracts, Glycyrrhiza uralensis extracts, grape extracts, extracts of fruits of plants belonging to the genus Alnus, Creeping saxifrage extracts, extracts of a flower of Rosa rugosavar. plena regel, tea extracts, superoxide dismutase, histidine, mannitol and carotenoids. The skin care preparation for external use having enhancing effects on the moisture-retaining properties contains the above medically effective component as an effective ingredient. The method for enhancing moisture-retaining properties of skin comprises supplying the medically effective component.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PURPOSE:Fine cellulose particles, obtained by incorporating viscose with a water-sluble anionic high polymer to form a fine particulate dispersion of the viscose and coagulating and neutralizing the resultant dispersion, consisting of cellulose II and having a sharp particle size distribution. CONSTITUTION:One pts.wt. viscose is incorporated with 0.03-100pts.wt. water- soluble anionic high polymer, e.g. having sulfonic acid groups, phosphonic acid groups, etc., to form a fine particulate dispersion of the viscose, which is then heated or mixed with a coagulating agent to coagulates the viscose. The coagulated viscose is then neutralized with an acid or the dispersion is coagulated with the acid and neutralized to from fine particles of the viscose, which are then separated from the mother liquor, and as necessary, desulfurized, washed with an acid and then water and dried to give the aimed fine cellulose particles, which are spherical or spheroidal particles, consisting of cellulose II, having 5-30% crystallinity, &lt;=20mum average particle diameter, and containing &gt;=70wt%, based on the total particles, particles having within + or -5mum particle diameter range.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an ACE inhibitor obtained by treating a nut with a protease, to provide a method for producing the same, and to provide a functional food containing the ACE inhibitor and having a hypotensive action.  &lt;P&gt;SOLUTION: The angiotensin I converting enzyme (ACE) inhibitor is obtained by treating the nut with the protease. The angiotensin I converting enzyme (ACE) inhibitor and the production method therefor can be provided by treating the nut with the protease. The raw material is the nut which is generally spread and is daily taken, and does not have any problem on the aspect of safety, when used as a food component. Since the nut as the raw material can be purchased at a low cost, the reduction in the production cost of the ACE inhibitor can be realized.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
1306613 Dyeing keratinic fibres L&#39;OREAL 30 June 1970 [8 July 1969] 31755/70 Heading D1B Keratinic fibres especially human hair are dyed by applying at least one coupling agent and at least one quinone-imine of an oxidation base in aqueous solution at a neutral or alkaline pH optionally in the presence of an oxidising agent. The quinone-imine may be formed from an aromatic or heterocyclic amine having two amino groups or an amino group and a hydroxy group which groups are ortho or para to one another any conventional coupling agent being used. Preferably the coupling agent is applied to the fibres for 5-20 mins followed by rinsing and application of the quinone-imine for 5-30 mins also followed by rinsing. Wetting, dispersing, swelling and penetrating agents may be present also direct dyes e.g. azo and anthraquinone dyes may be added. A two component pack comprises as first component a solution of a coupling component and as second component a quinone imine as a solution or as a powder.
Handheld medical diagnostic instrument that provides high time-resolution pulse waveforms associated with multiple parameters including blood pressure measurements, blood oxygen saturation levels, electrocardiograph (ECG) measurements, and temperature measurements. The device stores and analyzes the pulse waveforms simultaneously obtained from all tests, and thereby allows an unusually detailed view into the functioning of the user&#39;s cardiovascular heart-lung system. The device is designed for use by unskilled or semi-skilled users, thus enabling sophisticated cardiovascular measurements to be obtained in a home environment. Data from the device can be analyzed onboard, with local computerized devices, and/or with remote server based systems. The device or remote server may be configured to analyze this data according to various algorithms chosen by the physician to be most appropriate to that patient&#39;s particular medical condition (e.g. COPD patient algorithms). The device or remote server may be further configured to automatically provide alerts and drug recommendations.
&lt;P&gt;PROBLEM TO BE SOLVED: To detect and control accurate radiation exposure dose in radiographing a patient.  &lt;P&gt;SOLUTION: When performing radiography, firstly the total exposure dose aggregated for the patient S and his/her body regions photographed in the past is extracted from a database DB to determine whether the total past exposure dose is equal to or larger than a prescribed threshold value. If it is determined to be equal to or larger than the prescribed threshold value, a radiographic device 10 outputs an alarm to a radiation engineer. On the other hand, if it is determined that the total past exposure dose is below the prescribed threshold value, radiography begins with the radiographic device 10. In this case, not only the radiation exposure dose in this radiographing but all other exposure doses by preparatory radiation or radiation when imaging ends in failure are added together. When the radiography is finished, the required imaging exposure dose measured by an exposure dose measuring means 14 is transmitted to an exposure dose control means 20 through a network 2. Then, data for the radiography of this time is added to the data sheet of the patient S by a data aggregation means 21 of the exposure dose control means 20.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic offering excellent aroma intensity and preference even after sequential use.  &lt;P&gt;SOLUTION: The cosmetic includes a first agent and a second agent, provided that the second agent is sequentially used after the first agent. The first agent and the second agent each includes at least one ingredient I chosen from the group consisting of I-(a) citral etc. and I-(b) menthol etc. and at least one ingredient II chosen from II santalol etc., provided that the amount of the ingredient II compounded with the first agent is smaller than that compounded with the second agent.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
NEW MATERIAL:A polyaminedithiol compound of formula I (R1, R2, R11 and R12 are lower alkyl; R21 is H or lower alkyl; R3 and R13 are H or nitrogen- containing organic group, but at least one of the groups is the nitrogen- containing organic group). EXAMPLE:N-(2-Mercapto-2-methylprophyl)-N&#39;-(isoprophylaminomethyl-2- mercaptopropyl)ethylenediamine. USE:The compound of formula I produces a chelate bond with a radioactive metal element to form a chelate useful as a radioactive diagnostic agent. A complex thereof with Tc-99m is especially useful as a brain local blood flow- imaging agent. PREPARATION:For example, a compound of formula II (Pro is a mercapto- protecting group) is condensed with CO(Cl)2 to form a compound of formula III, which is reduced to convert the carbonyl groups thereof into methylene groups. The protecting groups of produced compound of formula IV are removed to provide a compound of formula I wherein all of R1, R2, R11 and R12 are methyl; R21 is H.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an enhancer for a biophylactic ability efficiently carrying out prophylaxis of infectious diseases of crustaceans by a safe, inexpensive and simple means and a feed and to provide a method for prophylaxis of the infectious diseases using the same.  &lt;P&gt;SOLUTION: The method for prophylaxis of the infectious diseases of the crustaceans comprises administering the enhancer for the biophylactic ability to the crustaceans. The enhancer for the biophylactic ability comprises a 2-6C organic acid or a salt thereof as an active ingredient. Propionic acid or a salt thereof is preferably used as the organic acid or salt thereof. Another method for prophylaxis of the infectious diseases of the crustaceans comprises supplying a feed for the crustaceans comprising an effective amount of the 2-6C organic acid or salt thereof thereto. The feed may contain 0.003-0.03 wt.% of the propionic acid.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
Cephaloglycine ester are of formula (I) and salts, and the intermediates are of formula (VIII) (where X&#39; is protected amino gp. which can be deprotected under neutral or acid conditions without cleaving the beta-lactam ring). (I) is prepd. by e.g. reacting a deriv. of Ph.CHX.COOH (X= opt. protected amino or an amino precursor gp.) with appropriate, opt. silylated, 7-amino cephem. (I) is hydrolysed in vivo to cephaloglycine which is a known antibacterial. Unlike cephaloglycine itself (I) is readily absorbed following oral administration to humans or animals and gives high serum levels of antibiotic.